Abstract: Provided herein are methods comprising the use of KRAS (e.g., hKRAS) inhibitors in combination with an agent(s) that specifically binds to EGFR (e.g., hEGFR) and TGF? (e.g., hTGF?), as well as compositions and kits comprising the same. The methods provided herein are useful in methods of treating cancer, (e.g., KRAS (e.g., hKRAS) variant cancers). Further provided herein are combination regimens, combination compositions, pharmaceutical compositions, and kits comprising a KRAS (e.g., hKRAS) inhibitor and an agent(s) that specifically binds to EGFR (e.g., hEGFR) and TGF? (e.g., hTGF?).

Abstract: Antibodies and compositions against IGF-1R and uses thereof are provided herein.

Abstract: A pharmaceutical composition of an anti-IL4R antibody and a use thereof, wherein the pharmaceutical composition includes the anti-IL4R antibody or an antigen binding fragment thereof, and a buffering agent; and the pharmaceutical composition can further include a surfactant and a stabilizer.

Abstract: The present invention discloses a nanobody targeting IL-6R? protein and uses thereof, wherein the heavy chain variable region of the nanobody comprises three complementary determining regions, CDR1, CDR2, and CDR3, wherein CDR1 has an amino acid sequence as shown in SEQ ID NO. 2, CDR2 has an amino acid sequence as shown in SEQ ID NO. 3, and CDR3 has an amino acid sequence as shown in SEQ ID NO. 4. With high affinity to IL-6R? protein and high stability and water solubility, the nanobody can be used in the development of pharmaceutical compositions for the treatment of IL-6-mediated related diseases or conditions, as well as in the development of reagents or kits for the detection of IL-6R?, which can provide potentially highly effective antibodies for the study of IL-6-mediated related diseases, and provide new therapeutic strategies and targets for autoimmune diseases or tumors.

Abstract: Provided are an antibody or antigen-binding fragment that specifically recognizes CD40, and a preparation method therefor and the use thereof.

Abstract: The present disclosure provides binding agents, particularly, antibodies, that comprise variable regions comprising humanized framework regions. Nucleic acids that encode one or both of the variable chains of the binding agents of the present disclosure are also provided, as are cells that include such nucleic acids. Also provided are compositions, including in some instances, pharmaceutical compositions, that include the binding agents disclosed herein. Methods of making and using the binding agents of the present disclosure are also provided. In certain aspects, provided are methods that include administering to an individual having a cell proliferative disorder a therapeutically effective amount of a binding agent disclosed herein, where the binding agent is administered to the individual to enhance an immune response, e.g., a T cell response, to abnormally proliferating cells. The binding agents are also useful in various diagnostic, and monitoring applications, which are also provided.

Abstract: Provided herein are methods of treating multiple myeloma (MM) using specific doses of an anti-B-cell migration antigen (BCMA) antibody and nirogacestat, and optionally, dexamethasone.

Abstract: The present disclosure describes antigen binding molecules, including antibodies, that specifically bind to the anti-CD20 scFv-14 or Gibbon ape leukemia virus gp70 protein, as well as molecules comprising the described sequences and cells presenting such molecules. The antigen binding molecules may be used in research, diagnostic, clinical, and other applications.

Abstract: The invention concerns ofatumumab for use in the treatment or prevention of pediatric multiple sclerosis (MS). According to the invention, ofatumumab is administered during a loading dose regimen at weeks 0, 1, 2 of the dosage regimen; and ofatumumab is administered during a maintenance dose regimen starting at week eight of the dosage regimen and continuing thereafter every six weeks.

Abstract: The present disclosure relates to the treatment of anti-PLA2R-positive membranous nephropathy. The anti-CD38 antibody, MOR202, is efficacious when administered to patients at certain dosage regimens.

Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from cancer. Specifically, the technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that one ISVD binds to TCR and at least two ISVDs bind to GPC3. The present technology also provides nucleic acids, vectors and compositions.

Abstract: The invention provides means and methods for inhibiting growth of a cancer. The means in some embodiments comprise proteins and antibodies that binds an extracellular part of a membrane associated member of the epidermal growth factor (EGF) receptor family and an extracellular part of a membrane associated member of a WNT signaling pathway. Further provided are various cells and assays that are helpful in the production of the proteins, antibodies and cells.

Abstract: The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.

Abstract: The present invention provides methods of testing anti-STn antibodies for their ability target cancer stem cells by isolating cancer stem cells from cultures, contacting them with anti-STn antibodies being tested, and measuring resulting cell viability.

Abstract: Provided are bispecific T Cell Engagers. More specifically, the invention is directed to bispecific molecules that bind to DLL3, MUC17 or CLD18 and activate CD (cluster of differentiation) molecules (e.g. CD3, CD28 and CD137). Also provided are methods of treating an ailment such as cancer using an antibody (or fragment) against DLL3, MUC17 or CLD18 paired with an antibody (or fragment) of an agonist antibody that activates CD3, CD28 and/or CD137.

Abstract: Provided herein is a method of treating or preventing acute or chronic lung disease in a subject, comprising administering an agent that modulates the expression of Serine Protease Inhibitor Kazal-type 1 (SPINK1) to the subject.

Abstract: The invention describes methods for administering anti-plasma kallikrein antibodies, e.g., dosing regimens, to treat plasma kallikrein associated disorders, including hereditary angioedema (HAE).

Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from TMA associated with hematopoietic stem cell transplant. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to TMPRSS2 and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections or influenza virus infections).

Abstract: The present invention concerns a method for preparing antigen binding proteins specific for PCSK9 with reduced viscosity. The method proceeds by replacing residues in high viscosity variable domain subfamilies with residues in correlating low viscosity subfamilies. The method further comprises substituting residues in the Fc domain with residues associated with low viscosity and adding charged residues to the C-terminus of the Fc domain. The present invention further concerns antigen binding proteins produced by this method.

Abstract: The present invention relates to a modified antibody comprising a heavy chain and a light chain, wherein the antibody is modified to include in one or more of its immunoglobulin polypeptide chains one or more first recognition site(s) for the transglutaminase from Kutzneria albida (KalbTG) or a functionally active variant thereof. The one or more first recognition site(s) are introduced at one or more selected position(s) within an antibody's heavy chain and/or an antibody's light chain.

Abstract: Compositions and methods for treating ovarian cancer are provided. Methods include combined treatment with chemotherapeutic agents and anti-STn antibodies. Chemotherapy resistant ovarian cancer cells may be reduced. Chemotherapy resistant ovarian cancer cells may include cancer stem cells.

Abstract: A strategy for site specific covalent modification of antibodies using a specialized targeting covalent heterobivalent ligand (cHBL), and corresponding design for a covalent heterobivalent inhibitor (cHBI) that can be used to prevent Immunoglobulin E (IgE) mediated allergic reactions triggered by drug molecules, according to one embodiment. These molecules contain four important components: (1) an IgE antigen binding site (ABS) ligand that can be a mimotope for the allergen protein, a small molecule, or a peptidomimetic, (2) an appropriate linker, which can be any flexible or rigid chemical linker, providing spacing between the ABS binder and the other moieties, (3) a nucleotide binding site (NBS) ligand, and (4) a reactive moiety to form a covalent link with an amino acid side chain of target IgE antibodies.

Abstract: A composition comprising a peptide nucleic acid (PNA) molecule comprising a nucleotide base sequence configured to bind to a target polynucleotide molecule; and a degron protein covalently bound to the PNA, wherein binding of the PNA to the target polynucleotide molecule causes degron mediated degradation of the target polynucleotide molecule.

Abstract: The present invention relates to a stabilized starch obtained by reacting under alkaline conditions a base starch having a protein content of less than 0.4% w/w with a reactant capable of forming active chlorine, wherein the reactant is used in an amount sufficient to provide between 4000 and 8200 ppm of active chlorine during the stabilization reaction.

Abstract: The present invention relates to a method for preparing an aqueous dispersion of opacifying pigment-binder hybrid particles that provides particle swelling and concomitant introduction of a binder layer without inhibition of polymerization. The composition prepared by the process of the present invention is useful for reducing the level of TiO2 in paints.

Abstract: A gas phase polymerization assembly comprising a gas phase polymerization reactor having at least one inlet and at least one outlet, a circulation gas compression unit having an inlet and an outlet, whereby the inlet of the circulation gas compression unit is fluidly connected to the at least one outlet of the gas phase polymerization reactor by an unreacted gas line; a flush gas compression unit having an inlet and an outlet, wherein the inlet of the flush gas compression unit is fluidly connected to the outlet of the circulation gas compression unit by a pressurized unreacted gas line; a circulation line fluidly connecting the pressurized unreacted gas line with the at least one inlet of the gas phase polymerization reactor; a flush gas withdrawal line connected to the outlet of the flush gas compression unit.

Abstract: A process for increasing a settled bulk density of a granular polyolefin polymer includes feeding a catalyst stream into a gas phase polymerization reactor, the catalyst stream comprising catalyst particles, optionally in slurry form by suspending in a mineral oil and/or other hydrocarbon liquid, contained in a carrier fluid; feeding a support gas into the gas phase polymerization reactor together with the catalyst stream entering the reactor, the support gas being fed into the gas phase reactor at a velocity; forming polyolefin particles in the gas phase polymerization reactor through contact with the catalyst particles and a monomer and optionally one or more comonomers; and determining a settled bulk density of the granular polyolefin particles, and, based on the settled bulk density, selectively increasing or decreasing the velocity of the support gas in order to maintain the settled bulk density above a preset limit.

Abstract: Materials and methods for conducting an atom transfer radical polymerization in the presence of oxygen by interlocking enzymatic activities are provided herein.

Abstract: Process for producing a supported metallocene catalyst system includes: (i) preparing mixture (a) by mixing a metallocene with a cocatalyst; (ii) preparing mixture (b) by reacting an aluminium (II) with an amine (III)t; wherein each R6 and R10 is hydrogen or a C1-30 hydrocarbon; R7, R8, and R11 are C1-30 hydrocarbon; R9 is hydrogen or a functional moiety comprising at least one active hydrogen; (iii) providing a support material, into a reaction vessel; (iv) providing a solvent into the reaction vessel; (v) supplying mixture (a) and mixture (b) to the reaction vessel; (vi) subjecting the contents of the reaction vessel to a temperature of >60° C. for a period of >3 hrs to obtain a supported catalyst system; and (vii) removing the solvent from the supported catalyst system. Such process allows for the production of a supported metallocene catalyst system having reduced fouling in olefin polymerisation.

Abstract: A crosslinkable polymer composition which provides a crosslinked product capable of both heat resistance and re-formability, a crosslinked polymer material capable of both heat resistance and re-formability, and an insulated wire and a wiring harness including the crosslinked polymer material. The crosslinkable polymer composition includes: ingredient A from which metal ion is released by heat; and ingredient B including an organic polymer having a side chain, including an electron-withdrawing substituent group capable of forming an ionic bond with the metal ion, and when B is crosslinked via the metal ion to form a crosslinked product, the product has a flow starting temperature of 190° C. or higher and 300° C. or lower. The crosslinked polymer material includes the crosslinked product of the crosslinkable polymer composition. The insulated wire includes a wire conductor, and an insulation coating including the crosslinked polymer material, and the wiring harness including the insulated wire.

Abstract: A polyvinyl ether-based polymer useful as a gellant, having a structural unit represented by formula (2): where R1 represents a linear or branched alkanediyl group having 1 to 5 carbon atoms, R2 represents a single bond or a linear or branched alkanediyl group having 1 to 5 carbon atoms, X represents —C(?O)OH, —C(?O)O-M+, or —C(?O)O?, M+ represents a counter ion, and n is an integer of 0 to 3.

Abstract: Provided are a novel dispersant for suspension polymerization, and the like. The dispersion stabilizer for suspension polymerization includes a polyvinyl alcohol-based polymer (A) having an acetal skeleton having an ionic group.

Abstract: A polar group-containing olefin copolymer comprising a structural unit (A) derived from at least one kind of monomer selected from the group consisting of ethylene and an olefin containing 3 to 20 carbon atoms, and at least one kind of structural unit (B) selected from the group consisting of a structural unit represented by the following general formula (I) and a structural unit selected from the following general formula (II): (reference numerals shown in the general formulae (I) and (II) are as described in the DESCRIPTION.

Abstract: A polyethylene composition having the following features: 1) a density from 0.957 to 0.968 g/cm3; 2) a ratio MIF/MIP from 12 to 30; 3) a MIF from 41 to 60 g/10 min.; 4) a long-chain branching index, LCBI, equal to or greater than 0.45; and 5) a ratio (?0.02/1000)/LCBI from 45 to 75.

Abstract: A free-radically polymerizable composition comprises at least one free-radically polymerizable compound, at least one transition metal acetylacetonate coordination complex having a neutral charge, and a photolabile reducing agent represented by the formula I R1, R2, and R3 a independently H or a C1-C18 hydrocarbyl group, and R4 is H or methyl. A method of polymerizing the free-radically polymerizable composition to provide an at least partially polymerized composition is also disclosed.

Abstract: Compounds, polymer compositions, systems, and methods for determining a concentration of a polymer composition in a fluid. The polymer compositions may include a copolymer that includes a tagging monomer. The copolymer may have a molecular weight of at least 1,000,000 Da (Mw). Methods for synthesizing compounds and polymer compositions.

Abstract: The present invention aims to provide an ester bond-containing polycarboxylic acid (salt) having a higher biodegradability and a higher alkaline degradation change rate, a method for producing the same, and a detergent composition containing the ester bond-containing polycarboxylic acid (salt). The present invention relates to an ester bond-containing polycarboxylic acid or a salt thereof, containing: an ester group-derived structural unit in a main chain; and a carboxylic acid or a salt thereof in a side chain, the carboxylic acid or the salt thereof being attached to a ? position or a ? position of a carbonyl carbon of the ester group.

Abstract: The present invention relates to a polymer latex for dip-molding applications obtainable by free-radical emulsion polymerization of a mixture of ethylenically unsaturated monomers comprising at least one conjugated diene and at least one ethylenically unsaturated nitrile compound in an aqueous medium in presence of seed latex particles having a glass transition temperature (mid point temperature Tmg) measured by DSC according to ASTM D3418-03 of ?50° C. to 50° C. wherein the seed latex particles do not contain structural units derived from ethylenically unsaturated nitrile compounds, to a method of preparing said polymer latex, to articles made by using said polymer latex and to a method for preparing dip-molded articles from said polymer latex.

Abstract: Embodiments of this disclosure provide a resin composition and an disclosure thereof. The resin composition includes a polyurethane acrylate and a curing monomer, the curing monomer includes a compound containing a free radical polymerizable group and/or a compound containing a moisture curable group, and a weight-average molecular weight of the curing monomer is greater than or equal to 300.

Abstract: The present application is directed to a copolymer obtained by free radical polymerization, said copolymer comprising, based on the total weight of monomers: from 0.01 to 10 wt. % of a) at least one co-polymerizable photoinitiator having an ethylenically unsaturated group and a moiety that is decomposable under photo-irradiation to form a radical; from 0.01 to 10 wt. % of b) at least one epoxy (meth)acrylate monomer having at least one (meth)acrylate group and at least one epoxide group; and, from 80 to 99.98 wt. % of c) at least one ethylenically unsaturated monomer which does not bear an epoxide group or a moiety decomposable under photo-irradiation to form a radical. The present application is further directed to a material which is crosslinkable under photoirradiation, said material comprising: a copolymer as defined above; and, at least one ionic photoacid generator (PAG).

Abstract: A method for producing an oxymethylene copolymer includes copolymerizing trioxane and a comonomer copolymerizable with the trioxane in a presence of a cationic polymerization catalyst and a polymerization controlling agent, wherein the polymerization controlling agent is a cyclic ether with a 4- or more-membered ring containing one oxygen atom.

Abstract: A process for the preparation of polycarbodiimides which also contain aziridine functions and which are not genotoxic. These aziridine-functional polycarbodiimides may be used as crosslinking agent.

Abstract: The present invention relates to aqueous polyurethane-vinyl polymer hybrid dispersions which are prepared by polymerisation, initiated by free radicals, of ethylenically unsaturated monomers and polyurethane prepolymers containing acid groups and hydroxyl groups, to a method for their preparation, and to their use particularly as coating binder in multilayer coatings.

Abstract: The present disclosure provides an extrudable article and a composition, each including at least one polyurethane including hydroxyl groups and latent isocyanate groups in the form of uretdione groups. The hydroxyl groups are present on a first polyurethane and the latent isocyanate groups are present on either the first polyurethane or a second polyurethane and a ratio of the latent isocyanate groups to the hydroxyl groups is greater than 1.2:1. A method of making the extrudable article is provided including reacting in an extruder a polymerizable composition including a uretdione-containing material including a reaction product of a diisocyanate reacted with itself, a hydroxyl-containing compound, and an isocyanate-containing compound. A method of making a core-sheath filament is provided including forming a core composition of the at least one polyurethane and wrapping a sheath composition including an ethylene copolymer or a polyolefin around the core composition.

Abstract: A poly(lactic acid-b-3-hydroxypropionic acid) block copolymer characterized in that mechanical properties of the block copolymer are excellent by introducing a lactide optical isomer-derived repeating unit and a poly(3-hydroxypropionic acid) repeating unit at the same time, and thus its application fields can be expanded.

Abstract: Embodiments of the present invention comprises one or more of an article composed of a copolymer, a copolymer made from a process, and a process for the preparation of a copolymer composition by metal free enzyme ring-opening polymerization of a monomer composition comprising i) an ethylene brassylate monomer; ii) a 1-4 dioxan-2-one (DO); iii) lipase B from Candida antarctica (Novozyme® 435) and at an elevated temperature, processing the monomer reactants i) and ii) to a copolymer via ring-opening polymerization under solvent-free conditions and a nitrogen atmosphere in the absence of a metal and the presence of the lipase to produce a random EB-co-DO copolymer.

Abstract: A polymer has a degradability and includes a monomer. The monomer of the polymer includes a benzene derivative, a lactide and a caprolactone. A ratio of the benzene derivative in the polymer is smaller than a ratio of the lactide in the polymer. The ratio of the benzene derivative in the polymer is smaller than a ratio of the caprolactone in the polymer.

Abstract: A fiber reinforced polyester polymer composition is disclosed that is specially formulated for food contact applications and/or medical applications. The polyester polymer composition contains glass fibers that are either bisphenol-A free or contain free bisphenol-A in only trace/residual amounts. The composition can be formulated without using conventional stabilizers, antioxidants and/or lubricants. The polymer composition displays excellent mechanical properties.

Abstract: The present specification relates to a resin including a poly (lactic acid-b-3-hydroxypropionic acid) block co-polymer, a resin composition including the same, and a resin molded article.